CAROLYN BLOUIR: Open Payments
NPI 1174024939 · PORTAGE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,161 in 68 payments from 16 companies in 2025. Trend: 2023 $1,190 · 2024 $1,508 · 2025 $1,161
Food & beverage: $1,161
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $279 |
| Novo Nordisk Inc | 11 | $173 |
| AstraZeneca Pharmaceuticals LP | 6 | $104 |
| GlaxoSmithKline, LLC. | 5 | $87 |
| Lilly USA, LLC | 4 | $72 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $57 |
| Merck Sharp & Dohme LLC | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Exact Sciences Corporation | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
Products named: VRAYLAR, Wegovy, UBRELVY, MOUNJARO, FARXIGA, JARDIANCE, TRELEGY ELLIPTA, REXULTI.
Industry payments across IN — which companies pay providers there.
